| Literature DB >> 26696133 |
Kyeong Eun Yang1, Hyun-Jin Jang1, In-Hu Hwang2, Young-Ho Chung1, Jong-Soon Choi1, Tae-Hoon Lee3, Yun-Jo Chung4, Min-Seung Lee5, Mi Young Lee6, Eui-Ju Yeo5, Ik-Soon Jang1.
Abstract
Phenyl-2-pyridyl ketoxime (Entities:
Keywords: cellular senescence; human diploid fibroblast; nitric oxide; phenyl 2-pyridyl ketoxime; reactive oxygen species
Mesh:
Substances:
Year: 2015 PMID: 26696133 PMCID: PMC4783342 DOI: 10.1111/acel.12429
Source DB: PubMed Journal: Aging Cell ISSN: 1474-9718 Impact factor: 9.304
Small molecules derived from the ECM in young HDFs
| Peak# | R. Time (min) | Corrected Area | Quality (%) | Name | CAS# |
|---|---|---|---|---|---|
| 1 | 3.97 | 4,113,313 | 91 | (R,S)‐Solketal | 100‐79‐8 |
| 2 | 4.66 | 15,529,445 | 89 | Trimethylethoxysilane | 1825‐62‐3 |
| 3 | 15.02 | 3,712,290 | 78 | Amyl nonanoate | 61531‐45‐1 |
| 4 | 17.76 | 6,417,032 | 75 | Myristamide | 638‐58‐4 |
| 5 | 19.51 | 18,934,505 | 89 | Palmitamide | 629‐54‐9 |
| 6 | 19.68 | 20,850,325 | 88 | Palmitamide | 629‐54‐9 |
| 7 | 21.28 | 400,389,362 | 95 | 9‐Octadecenamide | 301‐02‐0 |
| 8 | 21.44 | 15,726,569 | 89 | 9‐Octadecenamide | 301‐02‐0 |
| 9 | 26.54 | 3,952,246 | – | Hexamethylcyclotrisiloxane | 541‐05‐9 |
Compounds with quality (%) over 75% were listed.
Cyclotrisiloxane may be a contaminant derived from column‐coating materials.
Small molecules derived from the ECM in old HDFs
| Peak# | R. Time (min) | Corrected area | Quality (%) | Name | CAS# |
|---|---|---|---|---|---|
| 1 | 3.95 | 25,288,999 | 93 | (R,S)‐Solketal | 100‐79‐8 |
| 2 | 4.53 | 3,904,669 | 85 | Indole | 120‐72‐9 |
| 3 | 4.65 | 34,615,877 | 88 | Trimethylethoxysilane | 1825‐62‐3 |
| 4 | 15.02 | 4,825,192 | 78 | Amyl nonanoate | 61531‐45‐1 |
| 5 | 17.76 | 9,129,173 | 75 | Myristamide | 638‐58‐4 |
| 6 | 19.51 | 22,313,728 | 91 | Palmitamide | 629‐54‐9 |
| 7 | 19.68 | 24,528,236 | 88 | Palmitamide | 629‐54‐9 |
| 8 | 21.28 | 461,093,076 | 95 | 9‐Octadecenamide | 301‐02‐0 |
| 9 | 21.44 | 34,063,707 | 91 | 9‐Octadecenamide | 301‐02‐0 |
| 10 | 23.44 | 3,867,975 | 91 | Phenyl 2‐Pyridyl Ketoxime | 1826‐28‐4 |
Compounds with quality (%) over 75% were listed.
Figure 1(R,S)‐(±)‐2,2‐dimetyl‐1,3‐dioxolan‐4‐methanol and phenyl 2‐pyridyl ketoxime are small molecules enriched in the ECM of old HDFs. (A) Young and old HDFs were grown for 3 days. Cells were removed and nonpolar small ECM molecules from young and old HDFs were extracted and analyzed by GC/MS. The arrow heads indicate two major peaks that are increased in old ECM compared to young ECM. (B) The structures of (R,S)‐(±)‐2,2‐dimetyl‐1,3‐dioxolan‐4‐methanol [also known as (R,S)‐solketal] and phenyl 2‐pyridyl ketoxime (PPKO) obtained from ChemSpider online chemical database are shown. (C) HDF cells were grown for 1 day and treated with various concentrations (0.5, 1, 5 mM) of (R,S)‐solketal, (S)‐(+)‐solketal, and PPKO for 3 days. (D) HDF cells were grown for 1 day and treated with 1 mM PPKO for the indicated times (1–7 days). Culture media were changed every 2 days. Cell viabilities were determined using MTT assay, and percent viabilities are plotted as the means ± standard deviations of at least three experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with vehicle‐treated control cells.
Figure 2G2/M cell cycle arrest and senescence‐like changes induced by PPKO in young HDFs. A. Cell cycle analysis. B. SA‐β‐gal staining. C. Induction of senescence‐associated proteins in ketoxime‐treated young HDFs. (A) Young HDFs were cultured for 1 day and serum‐depleted by incubation with SFM for 1 day. The cells were then stimulated with 10% FBS in the presence of vehicle or 1 mM PPKO for 3–7 days. The cells were stained with PI, and the cell cycle was analyzed by flow cytometry. The percentage of cells at sub‐G1, Go/G1, S, and G2/M was plotted and shown on the right side. (B) Young HDFs were treated with vehicle (Y) or 1 mM PPKO for the indicated times (3–7 days). Old HDFs (O) were also treated with vehicle for control purposes. Cells were then stained with X‐gal to monitor SA‐β‐gal activities and photographed under an inverted microscope at 100×. (C) Young HDFs were treated with vehicle (Y) or 1 mM PPKO for 3–7 days, and cell lysates were then analyzed by Western blot analysis using antibodies against senescence‐associated proteins (P‐ERK1/2, Cav‐1, p53, p16ink4a, and p21waf1). β‐actin was used as an internal control. Bands in blots were normalized to β‐actin in each lane. Fold increases vs. levels in lane Y are written under each band.
Figure 3PPKO‐induced ROS generation was responsible for senescence‐like changes in young HDFs. (A and B) Young HDFs from passage 10 were grown for 1 day and treated with 1 mM PPKO for the indicated times (A: short‐term exposure 30 or 60 min, B: long‐term exposure 3–7 days). Cells were then treated with 10 μM DCF‐DA for 30 min. ROS generation was measured by flow cytometry. (C) Young HDFs were treated with vehicle (Y) or 1 mM PPKO for 0.5‐12 h (short‐term) or 3–7 days (long‐term), and cell lysates were separated by SDS‐PAGE. The protein levels of antioxidant enzymes (Prdx II, GPX I, catalase, SOD I, II and III) and β‐actin were assessed by Western blotting. Bands in blots were normalized to β‐actin in each lane. Fold increases vs. levels in lane Y are written under each band. (D) Young HDFs (Y) were pretreated with vehicle or antioxidants (10 mM NAC, 2 mM TEMPO, or 5 mM BSO) for 1 h and then treated with 1 mM PPKO for 3 days. Old HDFs (O) were also treated with vehicle for control purposes. Cells were then stained with X‐gal to monitor SA‐β‐gal activities and photographed under an inverted microscope at 100×.
Figure 4PPKO increased NO levels via iNOS induction. (A) Young HDFs (Y) were grown for 1 day and treated with 1 mM PPKO for the indicated times (0.5–24 h). Old HDFs (O) were treated with vehicle for control purposes. NO concentrations were assayed using an NO detection kit based on the Griess method. (B) Young HDFs were grown for 1 day and treated with 1 mM PPKO for the indicated times (0.5–24 h). NOS activities were determined as described in Materials and Methods. Levels of NO (A) and NOS activities (B) are plotted as the means ± standard deviation of at least three experiments. (C) Young HDFs were treated with vehicle (Y) or 1 mM PPKO (K) for the indicated times (0.5–24 h). Old HDFs were also treated with vehicle for control purposes. Cell lysates were separated by SDS‐PAGE, and the protein levels of iNOS and β‐actin were assessed by Western blotting. Bands in blots were normalized to β‐actin in each lane. Fold increases vs. levels in lane Y were calculated and are plotted as a bar graph (D). *P < 0.05, **P < 0.01, ***P < 0.001 compared with vehicle‐treated young HDFs (Y).
Figure 5The effect of iNOS inhibitors on PPKO‐induced NO production and SA‐β‐gal staining. (A) Young HDF cells (Y) were grown for 1 day and pretreated with vehicle or iNOS inhibitors (0.5 mM L‐NAME or 0.1 mM L‐NMMA) for 6 h and then treated with 1 mM PPKO (K) for the indicated times (0–8 h). NO concentrations were determined using an NO detection kit as described in Materials and Methods. (B) Young HDFs (Y) were pretreated with vehicle or iNOS inhibitors (L‐NAME or L‐NMMA) for 6 h and then treated with 1 mM PPKO (K) for 3 days. Cells were then stained with X‐gal to monitor SA‐β‐gal activities, and the stained cells were photographed under an inverted microscope at 100×.
Figure 6PPKO increased NO production via ROS‐dependent iNOS induction. (A) Young HDF cells (Y) were grown for 1 day, pretreated with vehicle or antioxidants (10 mM NAC or 2 mM TEMPO) for 1 h, and then treated with 1 mM PPKO (K) for the indicated times (0–2 h). NO concentrations were determined using an NO detection kit as described in Materials and Methods. (B) Young HDFs (Y) were pretreated with vehicle or antioxidants (10 mM NAC or 2 mM TEMPO) for 1 h and then treated with 1 mM PPKO (K) for the indicated times (1–2 h). Cell lysates were separated by SDS‐PAGE, and protein levels of iNOS and β‐actin were assessed by Western blotting. Bands in blots were normalized to β‐actin in each lane. Fold increases vs. levels in 0 h are written under each band. *P < 0.05 compared with vehicle‐pretreated young HDFs at 0 h after PPKO treatment.